OneSource Specialty Pharma reported a 12% year-over-year increase in revenue for Q2FY26, reaching $43.1 million. EBITDA surged by 37% YoY to $12.2 million, with EBITDA margin expanding to 28%. The company’s adjusted PAT turned profitable at $5.2 million. OneSource is also progressing with a proposed acquisition to strengthen its global footprint and capabilities, expecting closure by December 2026.

Q2FY26 Financial Highlights

OneSource Specialty Pharma has announced its financial results for the second quarter of fiscal year 2026, showcasing significant growth in revenue and profitability:

• Revenue: Increased by 12% year-over-year to $43.1 million.
• EBITDA: Rose by 37% year-over-year to $12.2 million, representing a 28% margin.
• Adjusted PAT: Improved from a loss to a profit of $5.2 million.

The company highlighted that the revenue increase was driven by MSAs execution and sales from its IP-led base business. DDC capacity addition is accelerating to support upcoming customer launches.

Proposed Acquisition

OneSource is set to strengthen its global presence through a proposed acquisition. As of September 30, 2025, the net debt for the incoming business stands at $11.5 million, expected to trend towards $7-8 million.

The acquisition is expected to add approximately $21 million in revenue and $7 million in EBITDA, with a 32% EBITDA margin (proforma). Key benefits include securing new partnerships, establishing a de-risked European platform for DDCs, gaining a wider base of experience in RTU and 505(b)(2) products, and expanding global reach for regional partners. The company anticipates closure by December 2026.

Business Outlook and Strategic Initiatives

OneSource is focusing on several key areas to drive future growth:

• DDC Capacities: Expanding capacity to support upcoming commercial supplies.
• Biologics: Seeing a significant boost in its biologics funnel through customer outreach and industry tailwinds, with approximately a 4x increase in the biologics funnel compared to FY25.
• Sustainability: Progressing towards stronger governance with integrated reporting and improved disclosure practices.

FY28 Financial Targets

The company has revised its FY28 financial outlook, projecting revenue of $400 million from organic growth, with an EBITDA margin of approximately 40%. Including the recently proposed acquisition, OneSource anticipates revenue exceeding $500 million with a targeted ROCE above 50%, a steady-state EBITDA margin of around 40%, and net debt-to-EBITDA below 1.5x.

Source: BSE

BLS International’s Board of Directors approved the unaudited financial results for the second quarter and half-year ended September 30, 2025. Additionally, Mr. Ajit Hugh Dias was appointed as Chief Human Resource Officer, effective November 11, 2025. The board also approved the closure of Reired BLS International Services Private Limited.

Financial Results Approved

The Board of Directors at BLS International has officially approved the standalone and consolidated unaudited financial results. This decision encompasses the second quarter (Q2: Jul-Sep) and half-year performance, concluding on September 30, 2025. These results have been reviewed by the Statutory Auditors.

Key Appointment: Chief Human Resource Officer

Mr. Ajit Hugh Dias has been appointed as the new Chief Human Resource Officer. His role as Senior Management Personnel is effective immediately, starting November 11, 2025. This appointment is expected to bolster the company’s human resources strategy and management.

Subsidiary Closure Approved

The board has given the green light for the closure, or strike-off, of Reired BLS International Services Private Limited. This entity was a wholly-owned subsidiary. The project for which it was incorporated did not materialize, leading to its closure. The minimal turnover for F.Y. 2024-25 was Rs. 2,00,000. The net worth for F.Y. 2024-25 was Rs. 30,467.

Reired BLS International Details

The expected completion date for the dissolution and strike-off of Reired is within 6 months, on or before 31st March, 2026. The company was incorporated for a specific project which was not materialized.

Source: BSE

Fortis Healthcare announced strong financial results for the second quarter of FY26. Consolidated revenue increased by 17.3% to ₹2,331 Cr. Operating EBITDA margin improved to 23.9%, and profit after tax rose significantly to ₹329 Cr, representing a 70.3% year-over-year increase. The hospital business and diagnostics divisions both contributed to the positive results.

Financial Performance Highlights

Fortis Healthcare reported robust financial results for Q2 FY26, demonstrating strong growth across its key business segments:

• Consolidated Revenue: Increased by 17.3% year-over-year to ₹2,331 Cr.
• Operating EBITDA Margin: Improved to 23.9% compared to 21.9% in Q2 FY25.
• Profit After Tax (PAT): Rose by 70.3% year-over-year to ₹329 Cr.

Segment Performance

Both the hospital and diagnostics businesses showed strong performance:

• Hospital Business Revenue: Grew by 19.3% to ₹1,974 Cr.
• Hospital EBITDA Margin: 22.9% versus 21.4% in Q2 FY25.
• Diagnostic Business Revenue: Increased by 7.1% to ₹357 Cr (net).
• Diagnostic EBITDA Margin: 29.1%.

Balance Sheet Update

The company’s net debt stood at ₹2,219 Cr as of September 30, 2025, with a net debt to EBITDA ratio of 0.96x.

Operational Updates

Fortis expanded its operational footprint with key developments:

• Entered a 15-year lease for a 200-bedded multi-specialty hospital in Greater Noida.
• Forged an Operations and Management (O&M) agreement for a 550-bedded greenfield super specialty hospital in Lucknow.

Key Performance Indicators (KPIs)

The hospital business demonstrated healthy KPIs:

• Occupancy: 71%
• ARPOB: ₹2.51 Cr per annum.

Specialty Performance

Focus specialties like Oncology and Renal Sciences demonstrated strong growth, increasing by 29% and 22%, respectively.

Source: BSE

Delhivery Ltd. reported significant growth and profitability in its Q2 FY26 earnings call. Express volumes increased by 32% year-over-year, and revenue from services reached ₹2,546 crores. The company completed the acquisition of Ecom Express, integrated its network, and saw improved margins across its business segments. Looking ahead, Delhivery is focused on continued growth, improving efficiency, and exploring new business opportunities.

Financial Performance Overview

Delhivery reported revenue from services of ₹2,546 crores for the quarter, demonstrating a year-over-year growth of approximately 16% and quarter-over-quarter growth of about 11%. EBITDA reached ₹150 crores, a substantial increase from ₹57 crores in Q2 of the previous year. The company reported a PAT of ₹59 crores, compared to 0.4% in the same quarter last year.

Express Parcel and PTL Segments

Express parcel shipments grew significantly, reaching 246 million shipments in the quarter, representing a 32.5% year-over-year increase. PTL demonstrated stable growth with 477K tons. PTL freight revenue grew 15% to ₹546 crores, with tonnage growing about 12%. The team has focused on expanding margins and ensuring profitable growth.

Ecom Express Integration

The acquisition of Ecom Express was completed in Q2. The revenue transition is largely completed, with net Ecom revenue for the quarter at ₹13 crores. The integration is progressing smoothly, with network rationalization complete and corporate overheads reduced by 85%. Integration costs were approximately ₹90 crores in Q2 and expected to remain between ₹100-110 crores over the next two quarters.

Operational Metrics and Key Initiatives

Delhivery’s PIN code reach remained consistent at 18,830. The number of active customers increased significantly, reaching approximately 48,000. The company has expanded its infrastructure to approximately 22.05 million square feet. Key initiatives include expanding supply chain services, exploring quick commerce, and focusing on improving profitability.

Margin and Growth Outlook

The company anticipates normalized express margins between 16% and 18%. Supply chain services have seen improved margins, scaling up from 7.2% to 12.8%. There are two new businesses on rapid commerce and Delhivery Direct with approximately ₹15 crores investment in the current quarter.

Source: BSE

PI Industries announced its Q2 FY26 results, highlighted by a 16% revenue increase to INR 18,723 Mn. New product introductions drove growth, particularly in Agchem Exports, up about 38% Y-o-Y. The company continues to invest in growth with capital expenditures of INR 4,415 Mn in H1 and positive traction in its Pharma segment, which saw 104% revenue growth in H1.

Financial Performance

PI Industries reported the following consolidated financial results:

• Q2 FY26 Revenue: INR 18,723 Mn (up 16% Y-o-Y)
• EBITDA: INR 5,434 Mn (down 14% Y-o-Y)
• PAT: INR 4,093 Mn (down 19% Y-o-Y)
• H1 FY26 Revenue: INR 37,728 Mn (up 12% Y-o-Y)
• EBITDA margin sustained at 28%

Key Highlights

• Agchem Exports experienced a volume decline of approximately 17% but new products grew about 38% Y-o-Y.
• Domestic revenue decreased by approximately 13% Y-o-Y due to erratic rainfall and regulatory transitions in Biologicals.
• Pharma revenue increased by 54% Y-o-Y, contributing about 4% of exports revenue.

Business Updates and Strategic Initiatives

• Positive momentum is reported in the Pharma segment with several on-boarded customers.
• The company is expanding its GMP site in Lodi, Italy and strengthening regulatory capabilities.
• The company commissioned a research center for plant systems to support global biologicals research.
• New registration for Bio-nematicide was filed in the US.

Outlook and Strategies

PI Industries anticipates some short-term industry volatility but remains focused on margin discipline, high-quality growth, and scaling strategic platforms. The company is leveraging technology, expanding its product pipeline, and pursuing inorganic growth opportunities to ensure long-term shareholder value creation.

Capital Allocation

The company maintains a debt-free balance sheet and continues to allocate capital towards manufacturing capabilities and R&D infrastructure, demonstrated by a Capex spend of INR 4,415 Mn in H1.

Source: BSE

Torrent Power has announced that the audio recording of its earnings conference call with analysts and investors for the quarter and half-year ended September 30, 2025 (Q2 FY26) is now available on the company’s website. Interested parties can access the recording through the provided link for insights into the company’s financial performance.

Earnings Call Audio Now Accessible

Torrent Power has made the audio recording of its recent earnings conference call available to the public. The conference call discussed the unaudited financial results for the quarter and half-year which ended on September 30, 2025, corresponding to Q2 FY26.

Accessing the Audio Recording

Investors and analysts can access the audio recording through the following link: https://www.torrentpower.com/public/pdf/investors//recording 202526 q2.mp3. This recording provides valuable insights into the company’s performance and management’s outlook.

Source: BSE

OneSource Specialty Pharma reported a 12% YoY revenue increase in Q2FY26, reaching ₹3,758 million. EBITDA grew by 37% YoY to ₹1,065 million, with margin expansion of approximately 506 bps. Adjusted PAT stood at ₹449 million with adjusted EPS of ₹3.9. The company is raising its FY28 revenue outlook to $500m+ following a proposed acquisition.

Q2FY26 Financial Performance

OneSource Specialty Pharma Limited announced its consolidated financial results for Q2FY26, ended September 30, 2025. Key highlights include:

• Revenues: ₹3,758 million, up 12% YoY
• EBITDA: Grew 37% YoY to ₹1,065 million
• EBITDA Margin: 28%, an expansion of approximately 506 bps YoY
• Adjusted PAT: Stood at ₹449 million with adjusted EPS of ₹3.9

H1FY26 Performance Overview

The company also reported on its performance for the first half of fiscal year 2026:

• Revenues: ₹7,030 million, up 12% YoY
• EBITDA: ₹1,950 million, up 37% YoY

Strategic Developments

The recently announced proposed acquisition of Poland and Brooks delivered a strong first half with combined revenue of $29 million and EBITDA of $11 million, translating into healthy margins of 38%.

Revised Outlook

Following the recently approved proposed acquisition for multi-dose fill-finish site in Europe and integrated carbapenem facility in India, OneSource is raising its FY28 revenue outlook to $500m+.

Source: BSE

Balrampur Chini Mills has announced an interim dividend of INR 3.50 per equity share for the financial year 2025-2026, as approved by the Board of Directors on November 11, 2025. The record date for determining shareholders’ eligibility is set for November 17, 2025. The company will deduct tax at source (TDS) on the dividend payout as per the Income-tax Act, 1961.

Interim Dividend Announcement

The Board of Directors of Balrampur Chini Mills Limited approved the declaration of an interim dividend at its meeting held on November 11, 2025. Shareholders can expect INR 3.50 per equity share for the financial year 2025-2026.

Key Dates and Tax Information

The record date to determine shareholders eligible for the interim dividend payout is November 17, 2025. As per amendments to the Income-tax Act, 1961, the company will deduct tax at source (TDS) at applicable rates. No tax will be deducted for resident individual shareholders if the total dividend paid during FY 2025-26 does not exceed INR 10,000.

Required Documentation for TDS

Resident shareholders must provide a valid PAN to avoid higher TDS rates. Shareholders can submit Form 15G/15H if their income is below the taxable limit to claim exemption from TDS. Non-resident shareholders must submit necessary documents such as Tax Residency Certificate (TRC) and Form 10F to avail treaty benefits. The documents should be submitted by November 17, 2025.

Source: BSE

Reliance Infrastructure has released the Monitoring Agency Report for the quarter ended September 30, 2025 (Q2 FY26). The report, submitted by Infomerics Valuation and Rating Limited, provides an overview of the utilization of proceeds from the company’s preferential issue of warrants. The report states that there were no deviations from the intended use of funds.

Monitoring Agency Overview

Infomerics Valuation and Rating Limited submitted a report on November 11, 2025, concerning the preferential issue of warrants by Reliance Infrastructure, covering the period up to September 30, 2025. The review was conducted based on the SEBI (Issue of Capital & Disclosure Requirements) Regulations, 2018.

Key Highlights from the Report

The report indicates that Reliance Infrastructure’s issuance comprised 12,56,00,000 warrants convertible into equity shares, with an issue price of ₹240.00 per share, amounting to a total of ₹3,014.40 crore. As of this report, no proceeds had been utilized during the reported quarter.

Financial Data Summary

Here’s a summary of the proceeds received and utilized (in ₹ crores):

• Total proceeds proposed: 3,014.40
• Proceeds received until December 2024: 753.60
• Utilized until December 2024: 482.25
• Unutilized balance by December 2024: 271.35
• Additional proceeds received until June 2025: 225.00
• Proceeds utilized until June 2025: 262.10
• Total Proceeds Received till September 30, 2025: 978.60
• Proceeds Utilized till September 30, 2025: 978.60

It was reported that 1,25,00,000 equity shares were allotted to Risee Infinity Private Limited on June 18, 2025, totaling a consideration of ₹300.00 crore.

Utilization and Deviation

There were no reported deviations from the intended purposes of the funds, and all arrangements are consistent with the offer documents.

Proposed Usage of Funds

A significant portion of the funds is earmarked for expanding the company’s presence in the defence sector and exploring new business opportunities, aligning with the ‘Make in India’ and ‘Viksit Bharat’ visions. Funds will also be deployed into general corporate purposes, up to 25% of issue proceeds.

Source: BSE